11.98

6.61% -0.87

Monte Rosa Therapeutics Inc (GLUE)

Overview News Price History Option Chain Financials Why GLUE Down? Discussions Forecast

Monte Rosa Therapeutics Inc stock is traded at $11.98, with a volume of 205.98K. It is down -6.61% in the last 24 hours and up +55.04% over the past month. Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Previous Close:

$12.85

Open:

$12.74

24h Volume:

205.98K

Relative Volume:

0.16

Market Cap:

$739.88M

Revenue:

Net Income/Loss:

$-130.41M

P/E Ratio:

-5.3482

EPS:

-2.24

Net Cash Flow:

$-67.76M

1W Performance:

-2.60%

1M Performance:

+55.04%

6M Performance:

+141.45%

1Y Performance:

+34.83%

1-Day Range:

$11.80

$12.99

1-Week Range:

$11.80

$13.22

52-Week Range:

$3.5001

$13.22

Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile

Name

Monte Rosa Therapeutics Inc

Sector

Healthcare (1137)

Industry

Biotechnology (635)

Phone

617-949-2643

Address

321 HARRISON AVENUE, BOSTON

Employee

142

Twitter

Next Earnings Date

Latest SEC Filings

GLUE's Discussions on Twitter

Compare GLUE with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GLUE Monte Rosa Therapeutics Inc	11.98	793.61M	0	-130.41M	-67.76M	-2.24
VRTX Vertex Pharmaceuticals Inc	420.67	109.11B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	632.59	68.50B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	434.00	60.25B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	815.91	50.39B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	181.01	40.44B	447.02M	-1.18B	-868.57M	-6.1812

Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-19-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Feb-15-24	Initiated	Wedbush	Outperform
Jan-03-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Oct-13-22	Initiated	UBS	Buy
Aug-15-22	Initiated	Jefferies	Buy
Apr-28-22	Initiated	Credit Suisse	Neutral
Feb-10-22	Initiated	Wells Fargo	Equal Weight
Oct-14-21	Initiated	SVB Leerink	Mkt Perform

View All

Monte Rosa Therapeutics Inc Stock (GLUE) Latest News

07:14 AM

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times

07:14 AM

04:31 AM

What to do if you’re stuck in Monte Rosa Therapeutics Inc.Dividend Hike & Low Risk Investment Opportunities - newser.com

04:31 AM

03:03 AM

Is it time to cut losses on Monte Rosa Therapeutics Inc.Market Volume Report & Stock Timing and Entry Methods - newser.com

03:03 AM

02:37 AM

Is Monte Rosa Therapeutics Inc. meeting your algorithmic filter criteriaJuly 2025 Decliners & Accurate Technical Buy Alerts - newser.com

02:37 AM

01:47 AM

Why Monte Rosa Therapeutics Inc. stock could benefit from AI revolutionWeekly Stock Report & High Return Trade Guides - newser.com

01:47 AM

01:22 AM

Chart based exit strategy for Monte Rosa Therapeutics Inc.2025 Top Gainers & Community Verified Trade Signals - newser.com

01:22 AM

Nov 02, 2025

Forecasting Monte Rosa Therapeutics Inc. price range with options dataMarket Movers & Safe Entry Trade Reports - newser.com

Nov 02, 2025

Cwm LLC Raises Holdings in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat

Nov 02, 2025

Nov 01, 2025